Concentration of nitric oxide products in bronchoalveolar fluid obtained from infants who develop chronic lung disease of prematurity

Archives of Disease in Childhood: Fetal and Neonatal Edition

Volumn 81, Issue 3, 1999, Pages

  Vyas, Julian R ^a   Currie, Andrew E ^a   Shuker, David E G ^a   Field, David J ^a   Kotecha, Sailesh ^a  

^a UNIVERSITY OF LEICESTER   (United Kingdom)

Author keywords

Bronchopulmonary dysplasia; Chronic lung disease of prematurity; Nitrate; Nitric oxide

Indexed keywords

INTERLEUKIN 1; INTERLEUKIN 6; NITRATE; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; NITRITE; TUMOR NECROSIS FACTOR;

ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE CLASSIFICATION; FEMALE; FETUS; HUMAN; INFLAMMATORY CELL; LUNG CIRCULATION; LUNG DYSPLASIA; LUNG LAVAGE; MALE; NEWBORN; PNEUMONIA; PREMATURITY; PRIORITY JOURNAL; RESPIRATORY DISTRESS SYNDROME;

EID: 0032745569     PISSN: 13592998     EISSN: 14682052     Source Type: Journal    
DOI: 10.1136/fn.81.3.F217     Document Type: Article

References (44)

1. Currie AE, Kotecha S. Chronic lung disease of prematurity. CritCareMed 1997;12:14-17.
2. Kotecha S, Silverman M. Chronic respiratory complications of neonatal disorders. In: Landau LI, Taussig LM, eds. Textbook of Pädiatrie Respiratory Medicine. St Louis: C V Mosby, 1998:488-521.
3. deLemos RA, Coalson JJ. The contribution of experimental models to our understanding of the pathogenesis and treatment of bronchopulmonary dysplasia. Clin Perinatol 1992;19:521-62.
4. Kotecha S, Chan B, Azam N. Increase in interleukin-8 and soluble intercellular adhesion molecule-1 in bronchoalveolar lavage fluid from preterm infants who develop chronic lung disease. Arch Dis Child Fetal Neonatal Ed 1995;72:F90-F6.
5. Kotecha S, Vangoo A, Silverman M, Shaw RJ. Increase in transforming growth factor-, concentration in bronchoalveolar lavage fluid from infants with chronic lung disease of prematurity. J Pediatr 1996; 128:464-9.
6. Kotecha S, Wilson N, Wangoo A, Silverman Ai, Shaw RJ. Increase in interleukin-l and interleukin-6 in bronchoalveolar lavage fluid from infants with chronic lung disease of prematurity. Pediatr Res 1996;40:250-6.
7. Watterburg KL, Carmichael DF, Gerdes JS, VC'erner S, Backstrom C, Murphy S. Secretory leukocyte protease inhibitor and lung inflammation in developing bronchopulmonary dysplasia. J Pediatr 1994;12S:264-9.
8. Jackson JC, Chi EY, Wilson CB, Truog WE, Teh EC, Hodson VA. Sequence of inflammatory cell migration into lung during recovery from hyaline membrane disease in premature newborn monkeys. Am Rev Respir Dis 1987;135:937-40.
9. Ogden BE, Murphy SA, Saunders GC, Pathak D, Johnson JD. Neonatal lung neutrophils and elastase/protease imbalance. Am Rev Respir Dis 1984:817-21.
10. Nathan C. Nitric oxide as a secretory product of mammalian cells. FASEBJ 1992;6:3051-64.
11. Lincoln J, Hoyle CHV, Burnstock G. Nitric oxide in health and disease. Biomédical research topics series: 1. Cambridge: Cambridge University Press. 1997.
12. Palmer RMJ, Ferrige AG, Moncada S. Nitric oxide release accounts for the biological activity of endothelium-derived relaxing factor. Nature 1987;327:524-6.
13. Ignarro LJ, Buga GM, Wood KS, Byrne RE, Chaudhuri G. Endothelium derived relaxing factor produced and released from artery and vein is nitric oxide. Proc NadAcad Sei USA 1987;84:9265-9.
14. Moncada S, Higgs A. Mechanisms of disease; the L-arginine nitric oxide pathway. N EnglJMcd 1993;329:2002-12.
15. Snyder SH. Nitric oxide: first in a new class of neurotransmhtets? Science 1992;2S7:494-6.
16. Kinsella JP, Parker TA, Galan H, Sheridan BC, Halbower AC, Abman SH. Effects of inhaled nitric oxide on pulmonary edema and lung neutrophil accumulation in severe experimental hyaline membrane disease. Pediatr Res 1997;41:457-63.
17. Iha S, Orita K, Kanno T, Utsume T, Sato EF, Inoue M, Utsumi K. Oxygen dependent inhibition of neutrophil respiratory burst by nitric oxide. Free Rad Res 1996;25:48998.
18. Niu X-F, Ibbotson G, Kubes P. A balance between nitric oxide and oxidants regulates mast cell-dependent neutrophil-endothelial cell interactions. Circ Res 1996;79:992-9.
19. Radomski MW, Palmer RMJ, Moncada S. Endogenous nitric oxide inhibits human platelet adhesion to vascular endothelium. Lancet 1987;ii:1047-8.
20. Kharitonov SA, Yates D, Robbins RA, Logan-Sinclair R, Shinebourne EA, Barnes PJ. Increased nitric oxide in exhaled air of asthmatic patients. Lama 1994;343:133-5.
21. Nelson BV, Sears S, Woods J, Ling CY, Hunt J, Clapper LM, Gaston B. Expired nitric oxide as a marker for childhood asthma. J Pcdiatr 1997;130:423-7.
22. Grasemann H, loannidis I, deGroot H, Ratjen F. Metabolites of nitric oxide in the lower respiratory tract of children. EurJPediatr 1997;156:575-8.
23. Vong HR, Carcillo JA, Burckart G, Kaplan SS. Nitric oxide production in critically ill patients. Arch Dis Child 1996;7-!:482-9.
24. Borland C. Endothelium in control. Br Heart J 1991;66:405.
25. Gaston B, Drazen JM, Loscalzo J, Stammler JS. The biology of nitrogen oxides in the airways. Am J Respir Crit Care Afafl994;149:538-51.
26. Stamler JS, Singel DJ, Loscalzo J. Biochemistry of nitric oxide and its redox-activated forms. Science 1992;258:1898-902.
27. Gaston B, Drazen JM, Loscalzo J, Stamler JS. The biology of nitrogen oxides in the airways. Am jf Respir Crit Care ^Icdl994;194:538-51.
28. Bancalari E, Abdenour GE, Feller R, Gannon J. Bronchopulmonary dysplasia: clinical presentation. J Pfdiatr 1979;95:819-23.
29. Grigg J, Arnon S, Silverman M. Fractional processing of sequential bronchoalveolar lavage fluid from intubated babies. Eur Respir J 1992;5:727-32.
30. Misko TP, Schilling RJ, Sah-emini D, Moore WM, Currie MG. A fluorometric assay for the measurement of nitrite in biological samples. Anal Biochem 1993;214:11-16.
31. Schmidt HHHW, Keim M. Determination of nitrite and nitrate by the Griess reaction. In: Feelisch M, Stamler JS, eds. Methods in nitric oxide research. Chichester: John ViIey, 1996:491-9.
32. Abman SH, Chatfield BA, Hall SL, McMurry IF. Role of endothelium-derived relaxing factor during transition of pulmonary circulation at birth. Am J Physiol 1990;Z59:H1921-H7.
33. Zellers TM, Vanhoutte PM. Endothelium-derived relaxations of piglet pulmonary arteries augment with maturation. Pcdiatr Res 1991;30:176-80.
34. Barnes PJ, Liew FY. Nitric oxide and asthmatic inflammation. Immunol Today 1995;16:128-30.
35. Barnes PJ. NO or no NO in asthma. Tliorax 1996;51:21820.
36. Can-away MS, Piantadosi CA, Jenkinson CP, Huang Y-C T. Differential expression of arginase and iNOS in the lung in sepsis. Exp Lung Res 1998;2-/:253-68.
37. Arkovitz MS, Szabo C, Garcia VF, Wong HR, Wispe JR. Differential effects of hvperoxia on the inducible and constitutive isoforms of nitric oxide synthase in the lung. Shock 1997;7:345-50.
38. Beckman JS, Koppenol VH. Nitric oxide, Superoxide and peroxynitrite: the good, the bad and the ugly Am J Physiol 1996;217:C1424-C37.
39. Kaur H, Halliwell B. Evidence for nitric oxide-mediated oxidative damage in chronic inflammation. FEES Lett 1994;350:9-12.
40. Haddad IY, Pataki G, Hu P, Galliani C, Beckman JS, Matalon S. Quantitation of nitrotyrosine levels in lung sections of patients and animals with acute lung injury. JClin Invest 1994;94:2407-13.
41. Moriel P, Abdulla DS. Nitrotyrosine bound to beta-VLDL apoprotein: a biomarker of peroxynitrite formation in experimental atherosclerosis. Biochem Biophys Res Commun 1997;32:332-5.
42. Hallman M, Bry K, Turbow R, Waffarn F, Lappalainen U. Pulmonary toxicity associated with nitric oxide in term infants with severe respiratory failure. J Pcdiatr 1998;132:827-9.
43. Yu'S-M, Hung L-M, Lin C-C. cGMP-elevating agents suppress proliferation of vascular smooth muscle cells by inhibiting the activation of epidermal growth factor signalling pathway. Circulation 1997;95:1269-77.
44. Kotecha S, Grigg J, Reinout RJ. ERS Task Force On Bronchoalveolar Lavage In Children: Special Consideration in Neonates. Eur Respir J (in press).